关注
Matthew Hadfield
Matthew Hadfield
在 brown.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Poly (ADP-ribose) polymerase inhibitors as cancer therapy
JF Hilton, MJ Hadfield, MT Tran, GI Shapiro
Front Biosci 18, 1392-1406, 2013
292013
Advances in liquid biopsy technology and implications for pancreatic cancer
AG Raufi, MS May, MJ Hadfield, AA Seyhan, WS El-Deiry
International journal of molecular sciences 24 (4), 4238, 2023
232023
Pharmacist intervention in colorectal cancer screening initiative
LM Holle, J Levine, T Buckley, CM White, C White, MJ Hadfield
Journal of the American Pharmacists Association 60 (4), e109-e116, 2020
172020
Harnessing artificial intelligence for prostate cancer management
L Zhu, J Pan, W Mou, L Deng, Y Zhu, Y Wang, G Pareek, E Hyams, ...
Cell Reports Medicine, 2024
102024
Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies
MJ Hadfield, R Helsing, JM Grant-Kels
Melanoma Research 30 (5), 429-432, 2020
102020
A fatal case of Immune thrombocytopenia secondary to the immune checkpoint inhibitor ipilimumab in a patient with BRAF wild type metastatic melanoma
MJ Hadfield, G Mui
Journal of Oncology Pharmacy Practice 26 (6), 1530-1532, 2020
62020
Updates in the treatment of non-metastatic castrate-resistant prostate cancer: the benefit of second-generation androgen receptor antagonists
MJ Hadfield, V Lyall, LM Holle, M Dennison
Annals of Pharmacotherapy 57 (11), 1302-1311, 2023
52023
Antiphospholipid syndrome presenting with splenic infarct
MJ Hadfield, JR Thumar
JCR: Journal of Clinical Rheumatology 27 (1), e19, 2021
52021
A rare case of clear cell adenocarcinoma of the cervix with no intrauterine diethylstilbestrol exposure
VM Thomas, SA Alexander, MJ Hadfield, J Vredenburgh
Cureus 12 (4), 2020
52020
Hyperprogression in PDL1 expressive, recurrent gastroesophageal-junction adenocarcinoma after pembrolizumab
S Sama, MJ Hadfield, NL Lia, J Vredenburgh
Cureus 11 (6), 2019
52019
Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R
MJ Hadfield, A Turshudzhyan, K Shalaby, A Reddy
Journal of Oncology Pharmacy Practice, 10781552211057867, 2021
42021
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)
MJ Hadfield, H Safran, MA Purbhoo, JE Grossman, JS Buell, BA Carneiro
Oncogene 43 (10), 758-762, 2024
32024
Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review
MJ Hadfield, K DeCarli, K Bash, G Sun, K Almhanna
International Journal of Molecular Sciences 25 (1), 543, 2023
32023
Neurologic complications of melanoma
JV Cohen, N Wang, VA Venur, MJ Hadfield, DP Cahill, K Oh, ...
Cancer 126 (3), 477-486, 2020
32020
Molecular and immune analysis of adrenocortical carcinoma (ACC): Implications for immune checkpoint inhibition (ICI).
B Nazha, N Gandhi, AR Naqash, MJ Hadfield, T Zhuang, JT Brown, ...
Journal of Clinical Oncology 41 (16_suppl), e16617-e16617, 2023
22023
Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma
A Turshudzhyan, M Hadfield, J Grant-Kels
Melanoma Research 31 (5), 421-425, 2021
22021
Amyloid deposition of the bilateral ureters in a patient with chronic systemic AL amyloidosis
MJ Hadfield, V Lyall, B Ristau, V Patel, J Hundal, H Kennedy, J Thumar
Urology 146, e10-e11, 2020
22020
Case of anthracycline-induced cardiogenic shock: a call to optimize modifiable cardiac risk factors prior to chemotherapy
A Gabriel, B Stringer, MJ Hadfield, M Madady
Cureus 11 (6), 2019
22019
Abnormal loss of weight
R Pettitt, SV Kota, I OMS, M Hadfield, OMS II
Osteopathic Family Physician 9 (2), 2017
22017
The evolving posology and administration of immune checkpoint inhibitors: Subcutaneous formulations
MJ Hadfield, DJ Benjamin, J Krell, J Warner, MP Lythgoe
Trends in Cancer, 2024
12024
系统目前无法执行此操作,请稍后再试。
文章 1–20